France Breast Cancer Drugs Market Size & Outlook, 2023-2030
France breast cancer drugs, 2018-2030 (US$M)
Related Markets
France breast cancer drugs highlights
- The France breast cancer drugs generated a revenue of USD 419.7 million in 2023 and is expected to reach USD 620.7 million by 2030.
- The France market is expected to grow at a CAGR of 5.7% from 2024 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Breast cancer drugs data book summary
| Market revenue in 2023 | USD 419.7 million |
| Market revenue in 2030 | USD 620.7 million |
| Growth rate | 5.7% (CAGR from 2023 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc |
Other key industry trends
- In terms of revenue, France accounted for 4.9% of the global breast cancer drugs in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
- Denmark is the fastest growing regional market in Europe and is projected to reach USD 76.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Drugs Scope
Breast Cancer Drugs Companies
| Name | Profile | # Employees | HQ | Website |
|---|
France breast cancer drugs outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 64.24% in 2023. Horizon Databook has segmented the France breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
France breast cancer drugs market is estimated to grow at a stagnant rate over the forecast period. Increasing prevalence of breast cancer is expected to drive the market over the forecast period.
Growing awareness of breast cancer in the country is another factor expected to drive overall market growth. For instance, Pink October was organized in 2018 as an awareness campaign by the association Le Cancer du Sein, Parlons-en in France.
Proactive government initiatives are mainly contributing to market growth. Increasing funding for R&D is also fueling market growth in France. Several clinical trials are being carried out to review and develop novel drugs for the treatment of breast cancer.
Reasons to subscribe to France breast cancer drugs databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of France breast cancer drugs databook
-
Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into France breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
France breast cancer drugs market size, by therapy, 2018-2030 (US$M)
France Breast Cancer Drugs Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
